Used in the treatment of autoimmune diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. It works by specifically binding to interleukin-17A (IL-17A), a pro-inflammatory cytokine involved in the pathogenesis of these conditions, thereby inhibiting its activity. This reduces inflammation, slows disease progression, and improves clinical symptoms including skin lesions and joint pain. It is administered via subcutaneous injection and is valued for its high specificity and efficacy in patients who do not respond adequately to other biologic therapies.